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Alzheimer’s disease (AD) is a devastating neurodegenerative condition with symptoms
of cognitive decline, behavioral disturbances, and ultimately mortality. As there is
currently no cure, improvements for management of AD symptoms are desperately
needed. The Citalopram for Agitation in Alzheimer’s Disease (CitAD) study exam-
ined off-label use of citalopram, a selective serotonin reuptake inhibitor, for man-
agement of agitation symptoms. The primary analysis showed a greater average
decrease in agitation symptoms and an increase in a potentially serious adverse event
with citalopram compared to placebo. Physicians want to know if the treatment
effect is heterogeneous, and if so, which patients have the greatest potential to ben-
efit; given the risks, it may be unethical to prescribe the drug to patients with little
chance of benefit. Subgroup analyses are employed to assess heterogeneity of effect
across subgroups defined by categorical baseline covariates. This is typically done
by calculating subgroup treatment effects in a stratified dataset and testing for the
interaction between treatment and the baseline covariate. This approach is not very
comprehensive, as it only examines one covariate at a time while patients hold mul-
tiple characteristics simultaneously. Another limitation of this approach is the use of
parametric models which carry the assumption of correct mean model specification.
For our subgroup analysis, we employed the two-stage estimation method developed
by Cai et al. [3]. In the first stage, parametric working models are used to calculate
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the approximate treatment effect, the difference in potential outcomes under citalo-
pram versus placebo, for each participant based on multiple baseline covariates. This
predicted treatment effect is called the index score; patients with the same combina-
tion of baseline covariates have the same index score and are considered a subgroup.
In the second stage, patients are grouped by index score allowing non-parametric
estimation of subgroup treatment effects using observed data. Using this approach,
we found evidence for treatment effect heterogeneity. CitAD participants with the
largest predicted treatment effects were more likely to be living outside long-term
care facilities, within the middle age range (ages 76-82), with minimal cognitive im-
pairment (MMSE 21-30), within the middle baseline agitation range (NBRS-A 6-8),
and not taking lorazepam.
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Alzheimer’s disease (AD) is a devastating neurodegenerative disease which currently
has no cure. The majority of people with AD are 65 or older; less than 5% of people
with the disease have “early onset”, characterized by diagnosis before age 65 [1].
AD is widely prevalent and will increase with the growing elderly population in the
developed and developing worlds. The estimated prevalence of AD was 5.3 million
in the United States in 2010 [1]. Worldwide, roughly 18 million are living with the
disease [13]. The worldwide prevalence is projected to reach 80 million by the year
2050 [7]. Without a cure, improvements in patient care and management of AD
symptoms are desperately needed to accommodate our aging population.
Alzheimer’s disease is a type of dementia. Dementia is a clinical syndrome char-
acterized by symptoms of severe cognitive and functional impairment [6]. Dementia
can be caused by an event like a stroke, or can be the manifestation of an under-
lying disease like Parkinson’s, Creutzfeldt-Jakob, or Alzheimer’s [1]. AD is by far
the largest attributable cause of dementia, accounting for an estimated 60-80% of all
cases [1]. The precise etiology of AD is unknown but is thought to have both genetic
and environmental components [5] [9]. Cognitive symptoms of AD include mem-
ory loss, confusion, difficulty recognizing people or places, impaired judgment, and
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problems with written and verbal communication [1]. In addition to cognitive impair-
ment, behavioral and psychological problems are also frequent among AD patients.
These symptoms can include verbal and physical aggression, agitation, anxiety, hal-
lucinations, paranoid delusions, depression, and other mood disorders [2]. It has been
estimated that more than 90% of AD patients will develop at least one behavioral or
psychological symptom within a 5 year period [2].
These behavioral and psychological symptoms of AD can be particularly difficult
for the patient and burdensome for the family and caregivers. Behavioral symptoms
are often the impetus for moving AD patients into long term care facilities [14]. Cur-
rent pharmacological treatments for AD symptoms of agitation and aggression include
antipsychotics, cholinesterase inhibitors, memantine, antidepressants, and anticonvul-
sants [2]. Antipsychotics have been widely used in the past, however recent findings
suggest limited efficacy and increased risk of serious adverse events including mor-
tality [2]. Alternatives such as antidepressants are encouraging, but are still lacking
data regarding safety and efficacy for this population. Citalopram is one such antide-
pressant, a selective serotonin reuptake inhibitor (SSRI), which has been suggested
as an alternative for the treatment of agitation in AD patients.
1.1 The CitAD clinical trial
The Citalopram for Agitation in Alzheimer’s Disease (CitAD) study design was pre-
viously described in detail by Drye et al. [4]. In summary, the CitAD study is a
randomized, multi-center, parallel, placebo controlled, double blinded clinical trial.
There were a total of eight clinical sites, located within the United States and Canada.
Consenting participants with probable Alzheimer’s disease and without depression
were randomized to either citalopram or placebo at a ratio of 1:1, stratified by center.
Each patient had a caregiver who also participated in the study by accompanying the
patient to all visits and providing information for patient evaluation. All caregivers
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received a structured psychosocial therapy which consisted of counseling sessions with
a trained study clinician. Patients were followed for a total of 9 weeks with assess-
ments made at enrollment and follow-up after 3, 6, and 9 weeks. Baseline covariates
including demographic information, severity of symptoms, and use of concomitant
medications were recorded for all participants at the enrollment visit. The primary
efficacy outcomes were agitation as measured by the modified Alzheimer Disease
Cooperative Study-Clinical Global Impression of Change (mADCS-CGIC) and the
Neurobehavioral Rating Scale agitation subscale (NBRS-A). Secondary efficacy out-
comes include cognition, functional impairment, mobility, and psychiatric symptoms.
There were 186 total participants with 92 randomized to placebo and 94 randomized
to citalopram. Loss to follow-up was relatively low; the week 9 primary efficacy out-
comes are available for 167 patients (81 randomized to placebo and 86 randomized
to citalopram).
1.2 Purpose
The purpose of this project is to examine treatment effect heterogeneity across par-
ticipants in the CitAD clinical trial and to identify potential predictors of citalopram
response. The primary safety and efficacy results of the CitAD trial were previously
presented by Porsteinsson et al. [12]. Patients receiving citalopram showed a signif-
icantly greater improvement in symptoms of agitation compared to those receiving
placebo, as measured by both primary outcomes; the difference in average change in
NBRS-A (week 9 - baseline) was -0.93 [-1.80, -0.06] favoring citalopram, and the odds
of improvement according to the mADCS-CGIC were 2.13 [1.23, 3.69] times larger in
the citalpram arm. The citalopram arm also showed a significant increase in a po-
tentially serious cardiovascular adverse event compared to placebo. Citalopram was
associated with a 18.1 [6.1, 30.1] millisecond greater increase in QTc interval than
placebo; 3 of 94 patients in the citalopram arm and 1 of 92 patients in the placebo
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arm experienced clinical QTc prolongation.
Although the average treatment effect estimate is informative, physicians ulti-
mately need to make treatment decisions on a patient-by-patient basis. Our post-hoc
subgroup analysis is motivated by the physician’s need to identify candidates who
have the most potential to benefit for prescribing purposes. Given the risks, it would
be unethical to prescribe citalopram to patients who have little chance of benefit.
However, the positive findings suggest that this drug may still be a good option for
a subset of Alzheimer’s patients. In this thesis, we propose methods for assessing
heterogeneity of affect and for characterizing the subset or subsets or patients who
would be most likely to benefit from treatment with citalopram.
1.3 Research questions
The CitAD study lends itself to the following three research questions:
1. What is the average treatment effect?
2. Are there subgroups of people for whom the treatment effect is larger than the
estimated average effect?
3. Is there evidence that there are groups that have different true average effects?
1.4 Subgroup analyses
Subgroup analyses are very common in randomized clinical trials. A self-study of the
New England Journal of Medicine found that 59 out of 97 total trials published from
July 2005 to July 2006 reported some form of subgroup analyses [8]. Similarly, another
study showed that 35 out of 50 trials sampled from four major medical journals in
1997 reported results from subgroup analyses [11]. Subgroup analyses appeal to the
current trends towards evidence based medicine. There may be true differences in
the risk or benefit of a treatment within different subgroups of people; knowing these
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differences would be very helpful to physicians in planning a course of treatment for
a particular patient. Typical subgroup analyses involve using parametric regression
models to look for interactions between treatment and each baseline covariate of
interest.
Subgroup analyses are often criticized for lack of power and high false positive rates
among reported subgroup effects. The sample size for a clinical trial is determined
by the number of participants needed to detect a minimum relevant effect size for
a given power. The power to detect the true treatment effect is greatly reduced
after dividing the total sample into smaller subgroups. Tests of interaction, such as
likelihood ratio tests, are recommended to evaluate heterogeneity among levels of a
baseline covariate [16] [11]. Multiplicity is also of great concern in subgroup analyses.
The null hypothesis of no treatment effect is tested multiple times, once for each
subgroup of interest, inflating the overall type I error rate. It is important to correct
for multiplicity in the analysis and also to limit the choice of subgroups to those which
have the most a priori biological or clinical support. If possible, possible subgroups
should be defined before the trial has begun to avoid the discovery and reporting of
spurious subgroup effects which have no biological basis.
Another limitation of the typical approach to subgroup analyses is the separate
evaluation of each baseline covariate. Subgroups are typically defined as the presence
of a single covariate level such as male or female gender. We would like to estimate
the treatment effect for a patient who carries several prognostic baseline traits si-
multaneously. One could consider each combination of baseline covariate levels as a
separate subgroup which is more realistic, however this becomes complicated as the
number of subgroups increases dramatically. An additional limitation of typical sub-
group analysis approaches is the use of parametric models which require numerous
distributional assumptions. Ideally, we would like to relax these assumptions and use
a non-parametric approach which relies more on the observed data.
Cai, Tian, Wong, and Wei introduced a novel two-stage subgroup analysis method
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which addresses both the need to evaluate combinations of several baseline covariates
simultaneously and the desire to obtain empirical estimates of the subgroup treatment
effects [3]. In the first stage, a parametric working model is chosen to describe the
approximate relationship between the outcome and several baseline covariates which
are thought to be prognostic. This parametric framework is used to generate an index
score for each patient which is the predicted treatment effect according to the working
models. Each index score can be considered its own subgroup corresponding to a
specific combination of baseline covariates. In the second stage, the index scores are
used to group participants in a way that allows the use of non-parametric methods
to ultimately estimate the subgroup treatment effects. We applied this two-stage
estimation procedure (with several modifications) to identify baseline predictors of
citalopram response and assess heterogeneity of treatment effect.
1.5 Summary
This thesis focuses on the application of the two-stage estimation procedure to the
CitAD study. The methods span several chapters. Chapter 2 includes a description of
the data and the traditional bivariate subgroup analysis methods. Chapter 3 provides
a step-by-step illustration of the two-stage estimation procedure introduced by Cai
et al [3]. Chapter 4 includes description of the hypothesis tests used to assess overall
heterogeneity of effect. Results specifically addressing each research question are
presented and discussed in Chapter 5. Concluding remarks are made in Chapter 6








The first of two primary outcomes of the CitAD trial was agitation as measured by
the modified Alzheimer’s Disease Cooperative Study-Clinical Global Impression of
Change (mADCS-CGIC). The mADCS-CGIC is a measure of how each participant’s
agitation symptoms at follow-up compare to his or her baseline symptoms, as evalu-









The study investigators are particularly interested in predicting which patients
will achieve either marked or moderate improvement for prescribing purposes. We
have thus created a mADCS-CGIC response variable which is an indicator for either
marked or moderate improvement (mADCS-CGIC 1 or 2) at week 9; this binary
variable is the outcome we used for the subgroup analyses. The sample size is 167
participants (86 randomized to citalopram and 81 randomized to placebo) for which
we have mADCS-CGIC response at week 9 and baseline covariate information. Of
these participants, 55 (34 randomized to citaloram and 21 randomized to placebo)
had a mADCS-CGIC response of either marked or moderate improvement at week 9.
The second primary outcome was agitation as measured by the Neurobehavioral
Rating Scale agitation subscale (NBRS-A). The NBRS-A subscale ranges from 0-18
where larger scores indicate more severe symptoms. In the CitAD study, baseline
NBRS-A scores ranged from 1-14, with mean and median scores of 7.6 and 8 respec-
tively. The NBRS-A scores at week 9 ranged from 0-16, with mean and median scores
of 4.7 and 4 respectively. A reduction of 50% from baseline NBRS-A is considered
a clinically relevant response by the study investigators. Of the available 167 partic-
ipants at week 9, 75 (48 randomized to citalopram and 27 randomized to placebo)
had at least 50% reduction in NBRS-A from baseline.
Our subgroup analyses focused on predicting mADCS-CGIC response rather than
NBRS-A improvement, as the study investigators feel that mADCS-CGIC response
is the more clinically relevant outcome. We have however, evaluated our predictive
model (based on mADCS-CGIC response) using both measures for comparison. We
would expect to observe any true subgroup effects consistently across closely related
outcomes [15].
2.1.2 Pre-specified subgroups
There were five baseline covariates which were pre-specified for subgroup analyses
in the CitAD protocol. The pre-specified baseline covariates are residency, presence
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of delusions and/or hallucinations, functional impairment, cognition, and agitation.
Residency was recorded at baseline as whether the patient resided in his own home,
a caregivers’ home, assisted living, or nursing facility. For the subgroup analysis, we
made a binary indicator for living in a long term care facility (including either as-
sisted living or nursing facilities). It should be noted that very few participants from
long term care facilities enrolled in the study (13 total, 12 of which were followed
through week 9). The Neuropsychiatric Inventory (NPI) is a survey completed by
the caregiver which assesses neuropsychiatric and behavioral symptoms. To assess
the presence of delusions and hallucinations, we used the NPI Delusions (NPI-D)
and NPI Hallucinations (NPI-H) subscales; each scale ranges from 0-12 where higher
scores indicate more severe symptoms. We created a binary indicator for presence of
hallucinations (NPI-H > 0) and/or delusions (NPI-D > 0) at baseline. Functional
impairment was measured by the Activities of Daily Living Inventory (ADL) survey
as completed by the caregiver. The ADL score ranges from 0-78 where higher scores
indicate less functional impairment. We created three subgroups defined by tertiles of
baseline ADL scores. Cognition was measured by the Mini Mental State Examination
(MMSE) which is a test administered by study personnel. MMSE scores range from
0-30 where higher scores indicate better functioning. We separated the participants
into three groups (mild to no impairment, moderate, and severe impairment) based on
MMSE cutoffs from the literature [10]. Baseline agitation was measured by the Neu-
robehavioral Rating Scale agitation subscale (NBRS-A). The NBRS-A ranges from
0-18 where higher scores indicate more severe symptoms. We created three subgroups
defined by tertiles of the baseline NBRS-A scores. The number and percentages of
participants in each pre-specified subgroup are provided in Table 2.1.
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Total Citalopram Placebo
Total Randomized 186 94 92
Residence
Home or relative 173 (93%) 86 (91%) 87 (95%)
Long term care 13 (7%) 8 (9%) 5 (5%)
Neuropsychiatric Inventory (NPI)
No hallucinations nor delusions 97 (52%) 52 (55%) 45 (49%)
Hallucinations and/or delusions 89 (48%) 42 (45%) 47 (51%)
Activities of Daily Living (ADL)
Largest tertile, 54-74 65 (35%) 39 (41%) 26 (28%)
Middle tertile, 31-53 64 (34%) 28 (30%) 36 (39%)
Smallest tertile, 6-30 57 (31%) 27 (29%) 30 (33%)
Mini-Mental State Examination (MMSE)
Mild to no impairment, 21-30 54 (29%) 32 (34%) 22 (24%)
Moderate, 11-20 81 (44%) 45 (48%) 36 (39%)
Severe, 0-10 51 (27%) 17 (18%) 34 (37%)
Neurobehavioral Rating Scale Agitation
Subscore (NBRS-A)
Smallest tertile, 1-5 52 (28%) 29 (31%) 23 (25%)
Middle tertile, 6-8 60 (32%) 34 (36%) 26 (28%)
Largest tertile, 9-14 74 (40%) 31 (33%) 43 (47%)
Table 2.1: Summary of pre-specified baseline subgroups
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2.1.3 Post-hoc subgroups
An additional six baseline covariates were selected for the subgroup analysis. These
post-hoc covariates are age, gender, and use of memantine, lorazepam, trazodone,
and cholinesterase inhibitors. Participant ages ranged from 47 to 92. Three age
subgroups were defined by tertiles of baseline age. Gender consists of male and female
subgroups; participants were roughly evenly divided between males and females. The
remaining post-hoc subgroups are indicators for the use of concomitant Alzheimer’s
medications within three weeks of enrollment. Use of these medications at enrollment
may serve as a proxy for severity of disease. These medications are typically used in
severe cases, especially lorazepam and trazodone which were also used as the rescue
drugs throughout the trial. The memantine, lorazepam, trazodone, and cholinesterase
inhibitor covariates each include two subgroups, one for users of each medication and
another for non-users. Users of cholinesterase inhibitors include patients who have
used donepezil, rivastigimine, and/or galatamine within three weeks of enrollment.




Total Randomized 186 94 92
Age
Smallest tertile, 47-75 57 (31%) 30 (32%) 27 (29%)
Middle tertile, 76-82 60 (32%) 29 (31%) 31 (34%)
Largest tertile, 83-92 69 (37%) 35 (37%) 34 (37%)
Gender
Male 101 (54%) 50 (53%) 51 (55%)
Female 85 (46%) 44 (47%) 41 (45%)
Memantine
No memantine use 108 (58%) 53 (56%) 55 (60%)
Memantine use 78 (42%) 41 (44%) 37 (40%)
Lorazepam
No lorazepam use 171 (92%) 88 (94%) 83 (90%)
Lorazepam use 15 (8%) 6 (6%) 9 (10%)
Trazodone
No trazodone use 167 (90%) 83 (88%) 84 (91%)
Trazodone use 19 (10%) 11 (12%) 8 (9%)
Cholinesterase Inhibitors
No cholinesterase inhibitor use 58 (31%) 32 (34%) 26 (28%)
Use of cholinesterase inhibitor(s) 128 (69%) 62 (66%) 66 (72%)
Table 2.2: Summary of post-hoc baseline subgroups
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2.2 Traditional subgroup analyses
We performed a series of simple bivariate analyses as a first look at potential sub-
group effects, and to later inform our covariate selections for the two-stage estimation
procedure. We estimated the treatment effect, the odds ratio of mADCS-CGIC re-
sponse in the citalopram group versus placebo group, within each subgroup using
logistic regression. In each logistic regression model, the log odds of mADCS-CGIC
response is regressed on treatment as a single predictor, as shown in Equation 2.1,
where E [Y |Z = z] is the probability of response for participants randomized to treat-
ment Z taking values of 0 for placebo and 1 for citalopram. The coefficient β1 is the
log odds ratio of response on citalopram versus placebo.
logit (E [Y |Z = z]) = β0 + β1z (2.1)
The results are provided in Figures 2.1 and 2.2 in the form of forest plots. The
forest plots provide the estimate and confidence intervals for the treatment effect
(odds ratio of response on citalopram versus placebo) for each covariate stratum.
Tests of interaction were done using likelihood ratio tests. The full model including
the interaction between the baseline categorical variable and treatment was compared
to the reduced model without this interaction. Equations 2.2 and 2.3 provide examples
of the full and reduced models respectively for a two-level covariate, X taking values
of 0 for the baseline level and 1 for the second level. The degrees of freedom for each
interaction test is equal to the number of covariate levels (subgroups) minus one.
logit (E [Y |Z = z,X = x]) =β0 + β1z + β2x+ β3(z × x) (2.2)
logit (E [Y |Z = z,X = x]) =β0 + β1z + β2x (2.3)
13
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Figure 2.1: Bivariate subgroup analyses for pre-specified covariates
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This two-stage estimation method was introduced by Cai, Tian, Wong, and Wei
in Biostatistics, 2011 [3]. In the first stage, a parametric working model (such as
a generalized linear model) is chosen as an approximation to the predictive true
regression of the dependent variable (outcome) on covariates which are thought to be
prognostic. The model is fitted separately for each treatment group using methods
that assume it is correct, for example, using weighted least squares. An index score
is then calculated for each patient as the difference in the fitted expected outcomes,
under assignment to treatment versus control group. In the second stage, a non-
parametric method is used to model the observed outcome as a function of the index
score for each treatment group separately. The difference in the two non-parametric
curves is a non-parametric estimate of the treatment effect for subgroups of patients
with the same index scores. In this chapter, we illustrate each of these steps using
the CitAD dataset. In addition to applying this procedure to our dataset, we have
made several modifications which aide in interpretation of results and also provide a
means for evaluating performance of this method.
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3.1 Stage 1: Generating the index scores
3.1.1 Covariate selection
To generate the index scores, we first had to decide which prognostic factors to include
in the working models. We selected the most promising baseline covariates based on
the results from the traditional bivariate subgroup analyses (Figures 2.1 & 2.2). We
decided to include baseline covariates for which the fold change in the treatment effect
(odds ratio, citalopram versus placebo) for any two levels is greater than three. The
five baseline covariates which meet this criteria are residency, MMSE, NBRS-A, age,
and lorazepam.
3.1.2 Defining the index score
For each prospective patient, we would like to predict his or her treatment effect
based on his or her baseline characteristics. In a causal inference framework, the
true treatment effect is the difference in the patient’s potential outcome if he or she
were given citalopram and the potential outcome if he or she were given placebo.











= g1(β1x)− g0(β0x) (3.2)
where Y(1) is the potential outcome if the patient were given citalopram, Y(0) is the
potential outcome if the patient were given placebo, and X = x is a vector of baseline
covariates (or functions of these values). As shown in Equation 3.2, the expected
value of each potential outcome can be approximated by a parametric model with
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design matrix, X=x, and covariate matrix, β. The functions g1 and g2 are smooth
link functions which relate the expected potential outcome to the linear predictor.
As defined in Cai et. al [3], the index score is an estimate for the true subgroup
treatment effect given by
ŝ(x) = g1(β̂1x)− g0(β̂0x) (3.3)
The vector of coefficients, β̂1, is estimated by fitting the working parametric model
with data from all participants randomized to citalopram. Similarly, β̂0 is estimated
by fitting the working model with data from all participants randomized to placebo.
Each model is fitted separately for each treatment group using weighted least squares.
The index score is the difference in the fitted values from the citalopram model and
the placebo model, and is the predicted treatment effect for each person according
to the working models. Each unique combination of baseline covariates corresponds
to a unique index score. Persons with the same index score can be thought of as
a subgroup. Persons with index scores which are close to one another have similar
predicted treatment effects.
3.1.3 Fitting the working models
The form of the working model for the binary mADCS-CGIC response outcome is
a logistic regression with five categorical predictors: residency, MMSE, NBRS-A,
age, and lorazepam. The estimated regression coefficients and their standard error
estimates are shown in Table 3.1 for citalopram and in Table 3.2 for placebo. These
coefficients would be used to calculate the index score for a new patient given his or
her baseline characteristics.
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Estimate Std. Error Z score p-value
(Intercept) -1.2657 0.7005 -1.81 0.0708
Residence: Long term care -0.7566 0.9423 -0.80 0.4221
MMSE: Moderate, 11-20 -1.3868 0.6067 -2.29 0.0223
MMSE: Severe, 0-10 -1.3019 0.7900 -1.65 0.0994
NBRS-A: Middle tertile, 6-8 1.5236 0.7315 2.08 0.0373
NBRS-A: Largest tertile, 9-14 2.3663 0.7579 3.12 0.0018
Age: Middle tertile, 76-82 0.7359 0.6389 1.15 0.2494
Age: Largest tertile, 83-92 0.1930 0.6485 0.30 0.7660
Lorazepam: User -0.0242 1.3041 -0.02 0.9852
Table 3.1: Citalopram working model coefficients
Estimate Std. Error Z score p-value
(Intercept) -1.6780 0.9513 -1.76 0.0777
Residence: Long term care 3.4785 1.5643 2.22 0.0262
MMSE: Moderate, 11-20 0.0268 0.8604 0.03 0.9752
MMSE: Severe, 0-10 -0.6216 0.9321 -0.67 0.5048
NBRS-A: Middle tertile, 6-8 -0.7819 1.0874 -0.72 0.4721
NBRS-A: Largest tertile, 9-14 1.9738 0.8238 2.40 0.0166
Age: Middle tertile, 76-82 -0.3326 0.7423 -0.45 0.6541
Age: Largest tertile, 83-92 -1.1348 0.8402 -1.35 0.1768
Lorazepam: User 2.2256 1.2938 1.72 0.0854
Table 3.2: Placebo working model coefficients
Calculating the index score for CitAD participants
The next step of the procedure is to calculate an index score for each of the 167 CitAD
participants. We have adjusted the calculation of the index score from that published
in Cai et al. [3] to avoid possible overfitting. Overfitting is a concern because we
use the participant’s observed response to fit the working model for the group that
the participant was assigned to in the trial. To avoid overfitting, we employ a leave-
one-out approach; we fit the working model for the assigned group with data from
all participants in that group except the participant for which the index score is
being calculated. The working model for the group which the participant was not
assigned is still fitted with the complete data from all participants in that group (same
coefficients as either Table 3.1 or Table 3.2). For participant i assigned to citalopram,
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the index score calculation is shown in Equation 3.4 where β̂1,−i is the vector of
estimated regression coefficients when the citalopram working model is fitted without
the ith participant. Similarly, the index score for participant i assigned to placebo is
given in Equation 3.5.
ŝ(x) = g1(β̂1,−ix)− g0(β̂0x) (3.4)
ŝ(x) = g1(β̂1x)− g0(β̂0,−ix) (3.5)
There were 68 unique index scores populated among the 167 participants ranging
from -0.920 to 0.693. Participants in the same treatment group with the same combi-
nation of baseline covariates received the same index score; as these participants are
essentially exchangeable, leaving one out resulted in the same regression coefficient
estimates and associated index score. The distribution of the index scores for the
CitAD participants is shown in Figure 3.1.
3.2 Stage 2: Non-parametric estimation of the treat-
ment effect
3.2.1 Visualizing the data
For each participant in the trial, we now have an index score, the observed mADCS-
CGIC (0 for non-response or 1 for response), and his or her treatment assignment.
To visualize this, we plotted each participant as a data point with the index score
on the x-axis and observed response on the y-axis as shown in Figure 3.2. Since the
values on the y-axis can only be 1 or 0, the points have been jittered to show all of the













Figure 3.1: Density of index scores
citalopram in red and placebo in blue. A loess smoother for each treatment group
is also shown to help visualize the distribution of responses across index scores. As
expected, the response probability increases with increasing index score in the citalo-
pram group. We might have expected a flat line near zero for the placebo group,
as the placebo should not have increased or decreased the probability of response.
However, there is an apparent negative association between index score and response
probability in the placebo group. There was a low level of response in the placebo
group (21 out of 81 participants) which is likely attributable to increased level of pa-
tient care and counseling which was provided to all caregivers. As shown in Table 3.2,
placebo response is associated with several working model covariates including base-
line severity of agitation. The index score is designed to predict differences between
the predicted responses (citalopram minus placebo), and so we observe higher placebo
response rates at low index scores and higher citalopram response rates at high index
scores. At the point where the curves cross, there is roughly no observed difference
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Figure 3.2: Plot of mADCS-CGIC response by index score
3.2.2 Non-parametric smoothing technique
We next use a smoothing technique to obtain a non-parametric estimate of the re-
sponse probability for each treatment group at each index score. Unlike the smoother
used in Cai et al. [3], we used a cumulative smoothing technique because it makes the
analysis easily interpretable. The non-parametric estimate of the response probability
for a particular index score is the proportion of persons with a response out of all
persons with an index score greater than or equal to the selected score. The left-most
estimate (corresponding to index score -0.920 or greater) is the average probability
of response for all participants. The right-most estimate is the proportion of persons
with a response at the largest index score, 0.693, alone.
A plot of the non-parametric estimates of the response probability by treatment
group is shown in Figure 3.3. The last step to obtaining the non-parametric estimates
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of the treatment effect is to subtract the estimates for the placebo group (shown in
blue) from the estimates for the citalopram group (shown in red) at each index score.
The resulting values are the non-parametric estimates of the treatment effect shown
in black in Figure 3.3. As an example of how to read and interpret the plots in
Figure 3.3, participants with index scores of 0.2 or greater comprise a subgroup for
which the estimated response probability under placebo is 0.167 and the estimated
response probability under citalopram is 0.525; the estimated treatment effect for this
subgroup is the difference in those probabilities, 0.358.
3.3 Confidence intervals
3.3.1 Point-wise confidence intervals
We created 1,000 bootstrap samples by sampling with replacement from the original
167 participants with available week 9 mADCS-CGIC data. Each bootstrap dataset
consists of 167 entries each with treatment assignment, the observed mADCS-CGIC
response, and index score (calculated from the original dataset). For each boot-
strapped dataset, we re-ran the cumulative smoother to obtain a new estimate of
the treatment effect at each index score. The empirical distributions of the 1,000
bootstrap estimates at each index score are the basis for point-wise 95% confidence
intervals as shown in Figure 3.5. The 0.025 quantile of each distribution is the lower
bound and the 0.975 quantile is the upper bound of the 95% confidence interval for
the treatment effect estimate at each index score.
3.3.2 Correcting for multiplicity
Because we are estimating these point-wise 95% confidence intervals for multiple index
scores (there are 68 unique index scores among the CitAD participants), we made a
correction for multiple comparisons to preserve the overall type I error rate. For each
23
● ● ● ● ●






























● ● ● ●● ● ● ●●● ● ● ● ● ●





























































Figure 3.3: Plots of response probability and treatment effect by index score
point-wise confidence interval, there is a 5% probability that the corresponding true
treatment effect value lies outside the bounds simply by chance. For the set of all
68 true subgroup treatment effects, the chance that any one of them lies outside the
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bounds is then necessarily larger than 5%. We need to apply a correction such that
the confidence bands cover all 68 true subgroup treatment effects simultaneously with
95% probability. The corrected confidence bounds will be wider than the point-wise
confidence intervals.
In Cai et al. [3], multiplicity is addressed by the calculation of a simultaneous
confidence interval in addition to the point-wise interval. The simultaneous confidence
interval is given by Equation 3.6 where δ̂i is the bootstrap treatment effect estimate
at the ith index score, σ̂i is the corresponding bootstrap standard error estimate, and
γ is a correction factor.
δ̂i ± γσ̂i (3.6)
The correction factor, γ, is the 95th percentile of the distribution of maximum
standard deviations of the treatment effect estimates from their means in each
bootstrap sample. Each bootstrap iteration produces 68 subgroup treatment effect
estimates. Each of these estimates can be given a standardized Z-score to represent
its distance from the mean (across all bootstrap samples) as shown in Equation 3.7,
where δij is the treatment effect estimate for index score i and bootstrap sample j,
σ̂i is the bootstrap standard error estimate, and δ̄i. is the mean of the bootstrap
treatment effects at index score i. The maximum Z-score for each bootstrap sample
is given by Equation 3.8. The correction factor γ is then the 95th percentile of the
distribution of 1,000 Zmax values. The distribution of 1,000 maximum Z-scores and
correction factor are shown in Figure 3.4. The correction factor after considering
multiple (68) looks is larger than 1.96 which means the simultaneous confidence
band will be wider than the point-wise confidence intervals. The point-wise and



















γ  = 2.83
Figure 3.4: Density of maximum Z-scores from 1,000 bootstrapped datasets
Instead of reporting both point-wise and simultaneous confidence intervals, we have
instead chosen to report a single 95% confidence interval which corrects for multiple
looks moving left to right. We think that the natural interpretation of the data is to
observe the average treatment effect (the estimate at the farthest left) and then
move right until a subgroup is found to have an estimated treatment effect which
significantly exceeds the average treatment effect. The index score for the first
estimated treatment effect moving left to right which meets this criteria defines the
largest subgroup for which we can say that the treatment effect exceeds the average.

























































Figure 3.5: Plot of treatment effect with point-wise and simultaneous 95% confidence
intervals
which takes into account all previous looks (to the left of that score). The
confidence interval to the far left is therefore the same as the point-wise interval and
the confidence interval to the far right is the same as the simultaneous interval. The
resulting plot is shown in Figure 3.6. The x-axis labels have been changed from the
index scores to the percent of CitAD participants with that index score or greater
for ease of interpretation. This also is the percentage of participants in each
subgroup. The orange line represents the average treatment effect, the probability
difference estimated from all participants.
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Figure 3.6: Plot of treatment effect and 95% confidence intervals after correcting for




4.1 Test for heterogeneity by index score deciles
We conducted a hypothesis test for overall treatment effect heterogeneity using the
two-stage estimation method without the cumulative smoother. Instead of using the
cumulative smoothing technique, we split the data into ten groups based on index
score deciles. We then calculated the non-parametric estimate of the treatment effect
within each decile; the non-parametric treatment effect estimate is the proportion of
observed responders in the citalopram group minus the proportion of responders in
the placebo group. We did the same procedure for 1,000 bootstrapped samples to get
a distribution of the treatment effect for each group which is shown in Figure 4.1.
The null hypothesis is that the treatment effect (difference in response probability)
is the same in all of the ten subgroups. The estimate of the common treatment effect is
the inverse variance weighted average of the ten individual treatment effect estimates







































































































Figure 4.1: Boxplot of bootstrap estimates of treatment effect at index score deciles













 = 0.173 (4.1)
We then used a likelihood ratio test to compare the null model with a common
treatment effect to the full model with a separate treatment effect estimated for each
decile. The likelihood ratio is shown in Equation 4.2. In this calculation, we assume
the decile estimates are independent; after examining the empirical correlation matrix,
this seems to be a reasonable assumption. The test statistic (TS) for the likelihood
ratio test is shown in Equation 4.3. This test statistic is compared to a χ2 distribution
with 9 degrees of freedom (the number of groups in the full model minus the number
in the reduced model). The resulting p-value (Equation 4.4) is very small suggesting










































P (TS ≥ χ29) = 0.00206 (4.4)
4.2 Comparison of the ten decile mean model with
a three mean model.
Looking at Figure 4.1, there appear to be three distinct groups: placebo responders
defined by decile 1, non-responders defined by deciles 2-8, and citalopram responders
defined by deciles 9-10. We hypothesize that this simpler, three group model is
adequate to describe differences in treatment effect across index scores instead of the
ten decile model. We used a likelihood ratio test to compare the reduced model with
three means to the full model with ten means. The test statistic is calculated as
previously shown, but the null common treatment effect estimate is replaced with the
inverse variance weighted average effect within each of the three groups. The test
statistic for this comparison is 1.46 which is compared to a χ2 distribution with 7
degrees of freedom (the number of groups in the full model minus the number in the
reduced model). The resulting p-value is 0.984, suggesting that the full ten decile
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model is not a significant improvement over the proposed three group model. The
boxplot for the three mean model is shown in Figure 4.2. The estimated treatment











































Figure 4.2: Boxplot of bootstrap estimates of treatment effect at three index score
subgroups
4.3 Test for consistent heterogeneity of NBRS-A
We would expect true differences across subgroups to be consistent among related
outcomes. The two primary outcomes of the CitAD study, mADCS-CGIC and NBRS-
A, both measure severity of agitation. To assess consistency of these subgroup effects
between the two measures, we did a hypothesis test for heterogeneity in the NBRS-A
outcome at the mADCS-CGIC index score deciles. We used the same method as
described in Section 4.1, except we calculated the non-parametric estimate of the
NBRS-A treatment effect within each decile. The non-parametric treatment effect
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estimate is the proportion of observed NBRS-A responders in the citalopram group
minus the proportion of responders in the placebo group where NBRS-A response was
defined as at least 50% reduction from baseline NBRS-A at week 9. This procedure
was repeated for 1,000 bootstrapped samples to obtain a distribution of the NBRS-A
treatment effect for each decile as shown in Figure 4.3. The likelihood ratio test for
the null hypothesis of a common treatment effect suggests no significant differences





































































































Figure 4.3: Boxplot of bootstrap estimates of NBRS-A treatment effect at mADCS-




In this chapter, we answer the original three research questions and interpret our
results. We will also relate the index scores back to the original baseline covariates
to propose which factors may be predictive of citalopram response.
5.1 Aim 1: What is the average treatment effect?
There is evidence that citalopram increases mADCS-CGIC response (marked or mod-
erate improvement of agitation symptoms) when compared to placebo. The estimated
average effect is a 0.136 difference in response probability (citalopram - placebo) with
a 95% confidence interval of [0.0134, 0.297]. The average treatment affect can be seen
in Figure 3.6 as the treatment effect estimate at the 100% percentile mark on the x
axis. This average treatment effect is an estimate of the difference in the potential
outcome if all of the study participants had been assigned to citalopram and the
potential outcome if they had all been assigned to placebo.
This finding is consistent with previous estimates of the average mADCS-CGIC
treatment effect. In the primary outcomes analysis, the average mADCS-CGIC treat-
ment effect estimate was an odds ratio of 2.13 (odds ratio of being at or better than a
given mADCS-CGIC category for citalopram versus placebo) with a 95% confidence
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interval of [1.23, 3.69] as estimated using ordinal logistic regression. The estimated
treatment effect from this analysis is smaller in magnitude than that reported in the
primary analysis; the difference between the two estimates is likely attributable to our
treatment of the original seven category mADCS-CGIC score as a binary response
variable. In the simple bivariate logistic regression analyses (Figures 2.1 & 2.2), the
average treatment effect estimate was an odds ratio of 1.87 (odds ratio of marked
or moderate improvement for citalopram versus placebo) with a 95% confidence in-
terval of [0.967, 3.61]. All estimates suggest that citalopram significantly improves
mADCS-CGIC scores compared to placebo.
5.2 Aim 2: Is there a subgroup with a larger than
average treatment effect?
From Figure 3.6 it is observed that there are several subgroups of patients for which
the entire confidence interval is above the average treatment effect of 100% of patients.
Moving from the left (the average treatment effect) to the right, the largest subgroup
for which the confidence interval almost exceeds the average treatment effect is the
subgroup of patients with the largest 60% of the index scores. The largest subgroup
for which confidence interval definitely exceeds the average treatment effect is the
subgroup with the top 20% of index scores.
This can be interpreted clinically by viewing the distribution of covariates for
these patients and comparing to the distribution of all patients. These comparisons
are made in Table 5.1 and Table 5.2. The distribution of covariates among all par-
ticipants is shown in Table 5.1. We then show the distribution of covariates among
the top 90% to 10% of index scorers in increments of 10%. The subgroup of the
top 60% has a larger distribution of participants living out of long term care, having
mild to no cognitive impairment (MMSE), in the middle tertile of baseline agitation
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symptoms (NBRS-A), in the middle age range, and not using lorazepam at baseline.
These trends become more prominent as you observe the distribution of covariates in
subgroups with larger average index scores.
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All Participants Top 90% Top 80% Top 70% Top 60%
Residence
Home or relative 155 (93%) 150 (99%) 134 (100%) 120 (100%) 100 (100%)
Long term care 12 (7%) 1 (1%) 0 (0%) 0 (0%) 0 (0%)
MMSE
Mild to no impairment 21-30 49 (29%) 46 (30%) 44 (33%) 44 (37%) 38 (38%)
Moderate, 11-20 75 (45%) 69 (46%) 56 (42%) 42 (35%) 36 (36%)
Severe, 0-10 43 (26%) 36 (24%) 34 (25%) 34 (28%) 26 (26%)
NBRS-A
Smallest tertile, 1-5 48 (29%) 43 (28%) 33 (25%) 19 (16%) 10 (10%)
Middle tertile, 6-8 55 (33%) 54 (36%) 53 (40%) 53 (44%) 51 (51%)
Largest tertile, 9-14 64 (38%) 54 (36%) 48 (36%) 48 (40%) 39 (39%)
Age
Smallest tertile, 47-75 54 (32%) 49 (32%) 34 (25%) 34 (28%) 23 (23%)
Middle tertile, 76-82 53 (32%) 50 (33%) 50 (37%) 46 (38%) 40 (40%)
Largest tertile, 83-92 60 (36%) 52 (34%) 50 (37%) 40 (33%) 37 (37%)
Lorazepam
No lorazepam use 156 (93%) 147 (97%) 131 (98%) 117 (98%) 99 (99%)
Lorazepam use 11 (7%) 4 (3%) 3 (2%) 3 (2%) 1 (1%)
Table 5.1: Baseline characteristics of subgroups with top 100% to 60% of index scores
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Top 50% Top 40% Top 30% Top 20% Top 10%
Residence
Home or relative 84 (100%) 68 (100%) 51 (100%) 35 (100%) 17 (100%)
Long term care 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
MMSE
Mild to no impairment, 21-30 38 (45%) 30 (44%) 23 (45%) 23 (66%) 17 (100%)
Moderate, 11-20 20 (24%) 13 (19%) 6 (12%) 6 (17%) 0 (0%)
Severe, 0-10 26 (31%) 25 (37%) 22 (43%) 6 (17%) 0 (0%)
NBRS-A
Smallest tertile, 1-5 10 (12%) 7 (10%) 0 (0%) 0 (0%) 0 (0%)
Middle tertile, 6-8 49 (58%) 41 (60%) 31 (61%) 26 (74%) 17 (100%)
Largest tertile, 9-14 25 (30%) 20 (29%) 20 (39%) 9 (26%) 0 (0%)
Age
Smallest tertile, 47-75 21 (25%) 9 (13%) 6 (12%) 6 (17%) 6 (35%)
Middle tertile: 76-82 36 (43%) 36 (53%) 29 (57%) 21 (60%) 8 (47%)
Largest tertile: 83-92 27 (32%) 23 (34%) 16 (31%) 8 (23%) 3 (18%)
Lorazepam
No lorazepam use 83 (99%) 68 (100%) 51 (100%) 35 (100%) 17 (100%)
Lorazepam use 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Table 5.2: Baseline characteristics of subgroups with top 50% to 10% of index scores
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5.3 Aim 3: Is the treatment effect truly heteroge-
neous?
There is evidence that there are groups with different true average effects. The p-value
of the hypothesis test for heterogeneity is 0.002 (Equations 4.2-4.4) which suggests
that the treatment effect is not homogeneous across all participants. This can also
be interpreted clinically by examining the distribution of covariates in each index
score subgroup. There are three distinct index score subgroups with different average
treatment effects as shown in Figure 4.2. These distribution of covariates in these
three subgroups are shown in Table 5.3.
The distribution of covariates in the subgroup with the largest index scores (deciles
9-10) are consistent with the patterns seen in Aim 2. We can also examine the
distribution of covariates in the subgroup with the lowest potential for benefit (decile
1); the covariate categories associated with reduced treatment effect are living in
long term care facilities, moderate to severe cognitive impairment, severe baseline
symptoms of agitation, being in the youngest age tertile (ages 47-75), and baseline
use of lorazepam.
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All Participants Decile 1 Deciles 2-8 Deciles 9-10
Residence
Home or relative 155 (93%) 10 (48%) 113 (99%) 32 (100%)
Long term care 12 (7%) 11 (52%) 1 (1%) 0 (0%)
MMSE
Mild to no impairment, 21-30 49 (29%) 3 (14%) 23 (20%) 23 (72%)
Moderate, 11-20 75 (45%) 11 (52%) 58 (51%) 6 (19%)
Severe, 0-10 43 (26%) 7 (33%) 33 (29%) 3 (9%)
NBRS-A
Smallest tertile, 1-5 48 (29%) 5 (24%) 43 (38%) 0 (0%)
Middle tertile, 6-8 55 (33%) 1 (5%) 28 (25%) 26 (81%)
Largest tertile, 9-14 64 (38%) 15 (71%) 43 (38%) 6 (19%)
Age
Smallest tertile, 47-75 54 (32%) 10 (48%) 38 (33%) 6 (19%)
Middle tertile, 76-82 53 (32%) 3 (14%) 29 (25%) 21 (66%)
Largest tertile, 83-92 60 (36%) 8 (38%) 47 (41%) 5 (16%)
Lorazepam
No lorazepam use 156 (93%) 14 (67%) 110 (96%) 32 (100%)
Lorazepam use 11 (7%) 7 (33%) 4 (4%) 0 (0%)




One strength of our analysis is the focus on baseline covariates which were pre-
specified in the protocol, although we also considered some plausible post-hoc co-
variates. All of the subgroup analyses that we have completed for the mADCS-CGIC
outcome have been presented in this report; we did not continue on a “fishing expe-
dition” to explore additional baseline covariates which may not have any biological
or clinical relevance. The cut-points to categorize/collapse the continuous and ordi-
nal baseline covariates were not pre-specified, but were chosen in a rather agnostic
manner. We based our decisions on clinically relevant values from the literature and
distribution tertiles, instead of searching for cutpoints which would yield the most
significant interactions. All of these aspects of our method enhance the credibility of
our results.
Although the subgroup covariates were selected before looking at any of the data,
the direction of the associations were not explicitly pre-specified. Our collaborators
from the study agree that the observed interactions seem plausible and have offered
various biological explanations. However, it is difficult to ascertain, after the fact,
whether the direction of the observed interactions were consistent with their original
expectations based on clinical practice or whether they had been influenced by seeing
the results. As these results have not yet been disseminated to all of the investigators,
a study has been proposed to conduct a survey to see how the naive clinician would
rank the significance and direction of the association between the treatment and each
of the covariates.
Of major concern for plausibility is the observed lack of consistency between the
mADCS-CGIC and NBRS-A treatment effects across the same subgroups. As both
primary outcomes measure severity of agitation, we would expect to see the same
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interactions using both measures if these subgroup effects are real. The observed lack
of treatment effect heterogeneity in the NBRS-A response across subgroups (Figure
4.3) reduces the credibility of our results somewhat. We are unsure whether the lack
of consistency is an indication that the proposed interactions are spurious effects or
if the lack of consistency is the product of disagreement between the two outcome
measures. As shown in Table 5.4, the cross-tabulation of week 9 mADCS-CGIC
response (marked or moderate improvement) versus week 9 NBRS-A response (>=
50% reduction from baseline), the two measures of agitation do not completely agree
with one another. This lack of agreement could be a result of how the original ordinal
scales were dichotomized. It is possible that we would see better agreement across
subgroups if the NBRS-A variable were treated as continuous or categorized in a
different way. Given the sample size, we may also not have the power to detect true





Table 5.4: Agreement between mADCS-CGIC and NBRS-A responses
5.4.2 Contribution to existing methodology
Our contribution to the two-stage estimation procedure is the use of the cumulative
smoothing technique to determine the largest group of patients for which the subgroup
treatment effect is significantly larger than the average. Additionally, we describe
this subgroup as the percent of participants with the highest index scores, providing
a means for evaluation of the index scoring system. The calculated index scores
depend on the selection of the working models. Currently there is no way to compare
the performance of different specifications of the working models, such as inclusion
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of different baseline covariates. An ideal index scoring system will efficiently group
or rank patients such that there is the largest differentiation between high treatment
effect and low treatment effect subgroups. One way of evaluating the performance of
the method would be to maximize the percent of participants in the largest subgroup
with an above average treatment effect.
5.4.3 Assumptions & limitations
The two-stage estimation procedure is subject to the assumption that the working
models are specified such that they are useful in ranking participants by their true
treatment effects. The working models are used to generate the index score which is
the predicted treatment effect for a subgroup of patients with the same combination
of baseline covariates. The non-parametric estimation methods depend on the fact
that these subgroups can be efficiently ranked according to their true treatment ef-
fects using the index scores. So the working models are not used for inference, but as
a tool to facilitate non-parametric estimation. The assumption is that the working
models are close enough to the true relationship to efficiently rank the subgroups.
This is less limiting than the typical assumption of correct specification required for
most parametric methods. We are not certain how sensitive this two-stage method
is to gross mis-specification of the working models. Other limitations include com-
plete case analysis which is subject to the assumption that the outcome was missing
completely at random, meaning that the missingness did not depend on previous re-
sponses or the missing value. This is likely not a valid assumption, however our results
should be fairly robust to this assumption as missingness rates were low (10% missing
primary outcomes at week 9 and full baseline information on all participants). To
relax this assumption, we could impute missing outcomes using observed data from
the participant’s index score decile.
There are several additional aspects of this analysis which may limit its usefulness
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in guiding actual clinical practice. Our collaborators have noted that it would be
useful to have subgroups based on concrete measures which are less subject to fluctu-
ation. While age and residency are very concrete measures, the MMSE and NBRS-A
scores may be subject to measurement error and random day-to-day fluctuations.
This was somewhat out of our control, as we tried to focus on subgroups which were
pre-specified in the protocol. Another limitation is that this analysis also does not
account for possible risks associated with citalopram. Clinicians must consider both
the potential benefits and risks in making prescribing decisions for each patient. This
would require the additional modeling of a risk profile for each patient, as the prob-
ability of adverse events is likely heterogeneous as well. Our current analysis should




In this thesis, we have illustrated how the novel two-stage estimation approach intro-
duced by Cai et al. [3] can be applied to a real clinical trial using the CitAD dataset.
Using this approach, we have identified several likely predictors of citalopram re-
sponse. CitAD participants with the largest predicted treatment effects were more
likely to be living outside long-term care facilities, within the middle age range of
CitAD participants (ages 76-82), with minimal cognitive impairment (MMSE 21-30),
within the middle baseline agitation range (NBRS-A 6-8), and not taking lorazepam.
These trends were also seen using traditional bivariate subgroup analysis methods,
however we did not have the power to detect any significant individual interactions
as the sample size was quite limited. The two-stage estimation procedure has allowed
us to consider combinations of multiple baseline factors simultaneously and calculate
non-parametric estimates of subgroup treatment effects. This approach has provided
more persuasive evidence for true treatment effect heterogeneity among CitAD par-
ticipants.
Concerns such as the lack of consistency between related outcomes and question-
able biological plausibility cast doubt on our findings. With this in mind, we advise
the reader to intperpret these results as exploratory or hypothesis generating rather
45
than confirmatory. Additional experimental or observational data will be required
to confirm the proposed interactions. Future research plans include a survey study
designed to more objectively assess clinical opinion on the biological plausibility of
the observed interactions. Future development of the method may include changing
the framework for calculation of the index score to improve prediction.
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